World Asset Management Inc grew its holdings in shares of McKesson Co. (NYSE:MCK) by 2.3% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 17,953 shares of the company’s stock after acquiring an additional 410 shares during the period. World Asset Management Inc’s holdings in McKesson were worth $2,413,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in MCK. Dimensional Fund Advisors LP increased its holdings in McKesson by 14.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,663,926 shares of the company’s stock valued at $183,813,000 after acquiring an additional 214,284 shares during the last quarter. Municipal Employees Retirement System of Michigan bought a new stake in McKesson in the 4th quarter valued at $600,000. Segall Bryant & Hamill LLC increased its holdings in McKesson by 7.5% in the 4th quarter. Segall Bryant & Hamill LLC now owns 2,861 shares of the company’s stock valued at $316,000 after acquiring an additional 200 shares during the last quarter. FMR LLC increased its holdings in McKesson by 6.2% in the 4th quarter. FMR LLC now owns 4,366,193 shares of the company’s stock valued at $482,334,000 after acquiring an additional 253,731 shares during the last quarter. Finally, Actinver Wealth Management Inc. bought a new stake in McKesson in the 4th quarter valued at $307,000. Institutional investors own 88.92% of the company’s stock.
In related news, CEO Brian Scott Tyler sold 1,488 shares of McKesson stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $125.49, for a total transaction of $186,729.12. Following the completion of the transaction, the chief executive officer now directly owns 12,192 shares of the company’s stock, valued at approximately $1,529,974.08. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Lori A. Schechter sold 2,766 shares of McKesson stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $133.59, for a total transaction of $369,509.94. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,174 shares of company stock worth $804,583. Insiders own 0.88% of the company’s stock.
Shares of McKesson stock traded up $1.92 during trading hours on Tuesday, reaching $143.20. The company’s stock had a trading volume of 23,510 shares, compared to its average volume of 1,086,137. The business’s 50 day simple moving average is $137.15. McKesson Co. has a one year low of $106.11 and a one year high of $148.23. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.58 and a current ratio of 1.02. The stock has a market cap of $25.90 billion, a PE ratio of 10.54, a P/E/G ratio of 1.42 and a beta of 1.11.
McKesson (NYSE:MCK) last posted its earnings results on Wednesday, May 8th. The company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.66 by $0.03. McKesson had a net margin of 0.02% and a return on equity of 29.02%. The firm had revenue of $52.43 billion for the quarter, compared to the consensus estimate of $53.14 billion. During the same period in the previous year, the firm posted $3.49 EPS. The business’s quarterly revenue was up 1.6% on a year-over-year basis. Research analysts anticipate that McKesson Co. will post 14.17 earnings per share for the current fiscal year.
MCK has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Hersha Hospitality Trust from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. Wolfe Research initiated coverage on shares of Iqvia in a report on Tuesday, April 2nd. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. reduced their price target on shares of Schlumberger from $42.00 to $41.00 and set a “neutral” rating on the stock in a report on Monday, July 22nd. Credit Suisse Group upgraded shares of StoneCo from a “neutral” rating to an “outperform” rating in a report on Monday, July 22nd. Finally, Guggenheim started coverage on shares of Adaptive Biotechnologies in a report on Monday, July 22nd. They issued a “buy” rating and a $47.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $146.00.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Article: What is a Reverse Stock Split?
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.